Office Action Predictor
Last updated: April 17, 2026
Application No. 16/582,428

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

Non-Final OA §112§DP
Filed
Sep 25, 2019
Examiner
SKELDING, ZACHARY S
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Genmab A/S
OA Round
5 (Non-Final)
60%
Grant Probability
Moderate
5-6
OA Rounds
3y 8m
To Grant
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
490 granted / 817 resolved
At TC average
Strong +42% interview lift
Without
With
+42.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
25 currently pending
Career history
842
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
8.7%
-31.3% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 817 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11-1-25 has been entered. Claims 56, 58-66, 71-74, 79-81, 84 and 85 are pending. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The prior rejection under 35 USC § 112(a) has been withdrawn in view of applicant’s claim amendments and remarks. The prior nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 11613575 has been withdrawn in view of applicant’s argument. Claims 56, 58-64, 66 and 71-73 stand rejected, and claims 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 18, 24, 25, 26 and 27 of U.S. Patent No. 11535679 (cited previously). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Claims 56, 58-64, 66 and 71-73 stand rejected, and claims 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19, 24, 25, 25 and 27 of U.S. Patent No. 11548952 (cited previously). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Claims 56, 58-64, 66 and 71-73 stand rejected, and claims 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 16, and 22-33 of U.S. Patent No. 11845805 (cited previously). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Claims 56, 58-64, 66 and 71-73 stand rejected, and claims 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 18 and 23-28 of U.S. Patent No. 11858995 (cited previously). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Applicant’s request that the ODP rejections set forth above be held in abeyance until allowable subject matter is indicated is acknowledged, but cannot be granted. Obviousness type double patenting rejections, whether provisional or not, cannot be held in abeyance. A double patenting rejection can be overcome, e.g., by a convincing rebuttal of the merits of the rejection, by amending the claims such that they are no longer anticipated and/or rendered obvious by the reference claims or by filing a proper terminal disclaimer. Claims 56, 58-64, 66, 71-73, 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 8, 13-16, 24, 29 and 30 of U.S. Patent No. 11608383 (cited on an IDS). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Claims 56, 58-62, 63, 64, 66, 71, 72, 73, 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 8-13 of U.S. Patent No. 11814437 (cited herewith). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. Claims 56, 58-62, 63, 64, 66, 71, 72, 73, 74, 79 and 81 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 12435154 (cited herewith). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims anticipate the instant claims. No claims are allowed. However, claims 65, 80, 84 and 85 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY S SKELDING whose telephone number is (571)272-9033. The examiner can normally be reached M-F 9-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Daniel E Kolker can be reached at 571-272-3181. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ZACHARY S SKELDING/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Sep 25, 2019
Application Filed
Dec 13, 2022
Examiner Interview (Telephonic)
Mar 22, 2023
Request for Continued Examination
Mar 27, 2023
Response after Non-Final Action
Jun 27, 2023
Non-Final Rejection — §112, §DP
Oct 03, 2023
Response Filed
Oct 30, 2023
Final Rejection — §112, §DP
Feb 02, 2024
Notice of Allowance
May 02, 2024
Request for Continued Examination
May 06, 2024
Response after Non-Final Action
Jan 14, 2025
Non-Final Rejection — §112, §DP
Apr 17, 2025
Response Filed
May 20, 2025
Final Rejection — §112, §DP
Aug 21, 2025
Notice of Allowance
Nov 21, 2025
Request for Continued Examination
Nov 24, 2025
Response after Non-Final Action
Jan 08, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600792
MONOCLONAL ANTIBODIES AND METHODS OF USE
2y 5m to grant Granted Apr 14, 2026
Patent 12590171
Anti-VHH Domain Antibodies and Use Thereof
2y 5m to grant Granted Mar 31, 2026
Patent 12583890
METHODS FOR CONTROL OF AN INFECTIVE DISEASE WITH A VACCINE
2y 5m to grant Granted Mar 24, 2026
Patent 12577289
SURROGATE CO-RECEPTORS FOR T CELLS AND METHODS OF USE
2y 5m to grant Granted Mar 17, 2026
Patent 12565535
CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+42.2%)
3y 8m
Median Time to Grant
High
PTA Risk
Based on 817 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month